Galectin‐3 and ST2 as predictors of therapeutic success in high‐risk patients undergoing percutaneous mitral valve repair (MitraClip)

Percutaneous mitral valve repair (PMVR) is an interventional treatment option in patients with severe mitral regurgitation (MR) and at high risk for open‐heart surgery. Currently, limited information exists about predictors of procedural success after PMVR. Galectin‐3 (Gal‐3) and suppression of tumorigenicity 2 (ST2) induce fibrotic alterations in severe MR and heart failure. We sought to examine the predictive value of Gal‐3 and ST2 as specific indicators of therapeutic success in high‐risk patients undergoing PMVR.

[1]  G. Barbati,et al.  Predicting device failure after percutaneous repair of functional mitral regurgitation in advanced heart failure: Implications for patient selection. , 2018, International journal of cardiology.

[2]  S. Neubauer,et al.  Metabolic remodeling in hypertrophied and failing myocardium: a review. , 2017, American journal of physiology. Heart and circulatory physiology.

[3]  H. Katus,et al.  Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure , 2017, Clinical Research in Cardiology.

[4]  C. Hamm,et al.  P1369Galectin-3 and ST-2 as predictors of therapeutic success in high-risk patients undergoing percutaneous mitral valve repair (MitraClip) , 2017 .

[5]  H. Tada,et al.  Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure , 2017, ESC heart failure.

[6]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[7]  J. Roos‐Hesselink,et al.  Matrix metalloproteinases as candidate biomarkers in adults with congenital heart disease , 2016, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[8]  Jeroen J. Bax,et al.  Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium. , 2015, European heart journal.

[9]  J. Januzzi,et al.  ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. , 2015, The American journal of cardiology.

[10]  Jagmeet P. Singh,et al.  Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study. , 2014, The Canadian journal of cardiology.

[11]  R. D. de Boer,et al.  The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure , 2014, Expert review of molecular diagnostics.

[12]  M. Rousseau,et al.  Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. , 2014, International journal of cardiology.

[13]  J. Hausleiter,et al.  Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. , 2013, Journal of the American College of Cardiology.

[14]  P. Boekstegers,et al.  Acute outcomes after MitraClip therapy in highly aged patients: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) Registry. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[15]  O. Alfieri,et al.  Guidelines on the management of valvular heart disease (version 2012). , 2012, European heart journal.

[16]  T. Feldman,et al.  Transcatheter mitral valve interventions: current status and future perspective. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[17]  K. Kuck,et al.  MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry , 2012, European journal of heart failure.

[18]  J. Lupón,et al.  Combined use of high‐sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure , 2012, European journal of heart failure.

[19]  Stefan Störk,et al.  Mode of Action and Effects of Standardized Collaborative Disease Management on Mortality and Morbidity in Patients With Systolic Heart Failure: The Interdisciplinary Network for Heart Failure (INH) Study , 2012, Circulation. Heart failure.

[20]  I. Piña,et al.  Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study , 2012, Circulation. Heart failure.

[21]  James F Antaki,et al.  Insanity of left ventricular assist therapy: doing the same thing and expecting different results. , 2011, Circulation. Heart failure.

[22]  O. Alfieri,et al.  Patient selection for MitraClip therapy impaired left ventricular systolic function. , 2011, Minerva cardioangiologica.

[23]  M. Enriquez-Sarano,et al.  Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy , 2011, Heart.

[24]  Saibal Kar,et al.  Percutaneous repair or surgery for mitral regurgitation. , 2011, The New England journal of medicine.

[25]  A. Wu,et al.  High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.

[26]  P. Clopton,et al.  Association of ST2 levels with cardiac structure and function and mortality in outpatients. , 2010, American heart journal.

[27]  Richard T. Lee,et al.  The IL-33/ST2 pathway: therapeutic target and novel biomarker , 2008, Nature Reviews Drug Discovery.

[28]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.

[29]  Philippe Ravaud,et al.  A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. , 2003, European heart journal.

[30]  Richard T. Lee,et al.  Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.

[31]  H. Eichler,et al.  Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. , 1995, The American journal of cardiology.

[32]  Volkmar Falk,et al.  2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.

[33]  M. A. O. Ignacio,et al.  How to cite this article , 2016 .

[34]  I. Piña,et al.  Galectin-3 in Ambulatory Patients With Heart FailureClinical Perspective , 2012 .

[35]  M. Cheitlin.  Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy , 2012 .